Provided is a pyrazole Compound which has an Inhibitory activity of SGLT1 or one of its pharmaceutically acceptable salts, Pharmaceutical composition that comprises and its pharmaceutical use in the treatment of Type II diabetes mellitus.Claim 1: a compound or pharmaceutically acceptable salts thereof represented by the General formula (1) wherein the aryl ring is c\u2086\u208b\u2081\u2080 CY (i), (ii) or (iii) cicloalquenilo cycloalkyl c\u2083\u208b\u2088 c\u2083\u208b\u2088 n is 0, 1, 2, 3, or 4 r\u00b9\u1d43 is represented (i) A Halogen Atom (ii), (iii) Hydroxy, carboxy, (4) an alkyl group c\u2081\u208b\u2086, (V) a group alquenilo c\u2082\u208b\u2088,A group Alquinilo c\u2082\u208b\u2088 (VI), (vii) c\u2081\u208b\u2086 alkoxy Group, a cycloalkyl Group c\u2083\u208b\u2086 (viii), (IX) a group haloalquilo c\u2081\u208b\u2086, (X) a group hidroxialquilo c\u2081\u208b\u2086 (XI), an alkoxy Group c\u2081\u208b\u2086alquilo c\u2081\u208b\u2086 (XII), a Group haloalcoxi c\u2081\u208b\u2086alquilo c\u2081\u208b\u2086 (XI, (ii) an alkyl group c\u2081\u208b\u2086sulfonilalquilo c\u2081\u208b\u2086 (XIV), a Group haloalquil c\u2081\u208b\u2086sulfonilalquilo c\u2081\u208b\u2086 (XV), a Group halodialquil c\u2081\u208b\u2086aminoalquilo c\u2081\u208b\u2086,(XVI) a Group cicloalquil c\u2083\u208b\u2086alquinilo c\u2082\u208b\u2086 (XVII), a Group haloalcoxi c\u2081\u208b\u2086 (18th), a carboxialcoxi c\u2081\u208b\u2086 Group, an alkyl group c\u2081\u208b\u2086sulfanilo (XIX), (XX), a Group alquilsulfonilo c\u2081\u208b\u2086 (XXI), a Group haloalquilsulfonilo c\u2081\u208b\u2086 (XXII) Group, an alkyl C \u2081\u208b\u2088carbonilo (XXIII), an alkyl group c\u2081\u208b\u2086oxicarbonilo,(XXIV) a group represented by the formula (2) (a) where r\u2075 is a hydrogen Atom or an alkyl group c\u2081\u208b\u2086 (b), and r\u2076 is an alkyl group c\u2081\u208b\u2086 (a) or (b) a haloalquilo c\u2081\u208b\u2086 Group, an alkyl group c\u2086\u208b\u2081\u2080 (XXV) of saturated Heter
